The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold.
暂无分享,去创建一个
Ulrik Jurva | Volker Schnecke | M. Waring | V. Schnecke | G. Robb | Anette Svensson Henriksson | Michael J Waring | P. Bonn | C. Westerlund | Peter Bonn | D Mikael Brink | Jonas Fägerhag | Graeme R Robb | Christer Westerlund | U. Jurva | J. Fägerhag | D. Brink | Anette Svensson Henriksson
[1] Michael J. Waring,et al. Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092 , 2011 .
[2] Michael J. Waring,et al. Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656 , 2012 .
[3] Roland K. Robins,et al. Potential Purine Antagonists. VI. Synthesis of 1-Alkyl- and 1-Aryl-4-substituted Pyrazolo[3,4-d]pyrimidines , 1956 .
[4] Scott Boyd,et al. Discovery, synthesis and biological evaluation of novel glucokinase activators. , 2005, Bioorganic & medicinal chemistry letters.
[5] E. Kilgour,et al. PDH kinase inhibitors: a novel therapy for Type II diabetes? , 2005, Biochemical Society transactions.
[6] P. Siekevitz,et al. ENZYME-STRUCTURE RELATIONSHIPS IN THE ENDOPLASMIC RETICULUM OF RAT LIVER , 1962, The Journal of cell biology.
[7] H. Najafi,et al. Glucokinase and glucose homeostasis: proven concepts and new ideas. , 2005, Biochemical Society transactions.
[8] Giuseppe d'Annunzio,et al. Insights into the Structure and Regulation of Glucokinase from a Novel Mutation (V62M), Which Causes Maturity-onset Diabetes of the Young* , 2005, Journal of Biological Chemistry.
[9] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[10] M. Coghlan,et al. Glucokinase activators in diabetes management , 2008, Expert opinion on investigational drugs.
[11] Teruyuki Nishimura,et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.
[12] M. Coghlan,et al. Small molecule glucokinase activators as novel anti-diabetic agents. , 2005, Biochemical Society transactions.
[13] F. Matschinsky,et al. Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.
[14] Craig S Donald,et al. Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. , 2006, Bioorganic & medicinal chemistry letters.
[15] H. Lazrek,et al. Synthesis of Some 4‐Substituted 1‐(4‐Hydroxybutyl)Pyrazolo‐[3,4‐D]Pyrimidine Analogues of 9‐(4‐Hydroxybutyl)Guanine (HBG) , 2010 .
[16] M. Fyfe,et al. Glucokinase activators as potential antidiabetic agents possessing superior glucose lowering efficacies , 2009, Drugs of the Future.
[17] D. Mckerrecher,et al. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life. , 2011, Bioorganic & medicinal chemistry letters.
[18] Michael J. Waring,et al. Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators , 2011 .
[19] M. Tadayyon,et al. Insulin sensitisation in the treatment of Type 2 diabetes , 2003, Expert opinion on investigational drugs.
[20] F. Matschinsky. Regulation of Pancreatic β-Cell Glucokinase: From Basics to Therapeutics , 2002 .